Teva Pharmaceutical Industries Ltd. and UK-based Heptares Therapeutics, a subsidiary of Tokyo-based Sosei Group have announced a licensing of its migraine treatment candidates.
Under the agreement Teva will receive exclusive global rights to develop, manufacture and commercialize novel, small-molecule calcitonin gene-related peptide (CGRP) antagonists discovered by Heptares for the treatment of migraine.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
Heptares will receive an advance payment of $10 million, and is eligible to receive milestone payments of up to $400 million, on top of which it will be in line for royalties on net sales of products resulting from the collaboration.
“CGRP antagonism represents an exciting opportunity to treat migraine. We believe small-molecule CGRP antagonists offer further opportunities that are highly complementary to our promising candidate, TEV-48125, an anti-CGRP antibody, ” said Dr Michael Hayden, president of Global Research & Development and the chief scientific officer at Teva.
Malcolm Weir, chief executive officer of Heptares, said: “Teva brings world-leading clinical and commercial expertise in migraine to advance this program based on differentiated small-molecule CGRP antagonists discovered using our novel structure-based drug design technologies. The commitment Teva is making allows us to expand this promising program.”
